Results 211 to 220 of about 187,458 (237)

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.

Journal of Medicinal Chemistry
Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, is an essential effector of B-cell receptor (BCR) signaling. Chronic activation of BTK-mediated BCR signaling is a hallmark of many hematological malignancies, which makes it an ...
Daniel W Robbins, M. Noviski, Ying Siow (May) Tan, Z. Konst, Aileen M. Kelly, Paul Auger, Nivetha Brathaban, Robert Cass, Ming Liang Chan, G. Cherala, Matthew C Clifton, Stefan Gajewski, Timothy G Ingallinera, Dane Karr, Daisuke Kato, Jun Ma, J. McKinnell, J. Mcintosh, Jeffrey T. Mihalic, Brent Murphy, Jaipal Reddy Panga, Ge Peng, Janine Powers, L. Perez, Ryan Rountree, A. Tenn-McClellan, Arthur T. Sands, Dahlia R. Weiss, Jeffrey Wu, Jordan Ye, C. Guiducci, Gwenn H. Hansen, Frederick Cohen   +32 more
semanticscholar   +1 more source

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.

Journal of Medicinal Chemistry, 2022
Jingyu Zhang, J. Che, Xiaomin Luo, Mingfei Wu, Wei-juan Kan, Yuheng Jin, Hanlin Wang, Ao Pang, Cong Li, Wenhai Huang, Shenxin Zeng, Weihao Zhuang, Yizhe Wu, Yongjin Xu, Yubo Zhou, Jia Li, Xiaowu Dong   +16 more
semanticscholar   +1 more source

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

Journal of Medicinal Chemistry, 2018
J. Crawford, Adam R. Johnson, D. Misner, L. Belmont, G. Castanedo, R. Choy, Melis Coraggio, Liming Dong, C. Eigenbrot, R. Erickson, N. Ghilardi, Jonathan Hau, A. Katewa, P. B. Kohli, Wendy Lee, J. Lubach, Brent S. McKenzie, D. Ortwine, Leah K Schutt, Suzanne Tay, Binqing Wei, K. Reif, Lichuan Liu, H. Wong, W. Young   +24 more
semanticscholar   +1 more source

Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors

American Journal of Clinical Dermatology, 2020
V. Sibaud, M. Beylot‐Barry, C. Protin, E. Vigarios, C. Récher, L. Ysebaert   +5 more
semanticscholar   +1 more source

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.

Science, 1993
D. Rawlings, D. Saffran, S. Tsukada, D. Largaespada, J. Grimaldi, L. Cohen, R. Mohr, J. Bazan, Maureen Howard, N. Copeland   +9 more
semanticscholar   +1 more source

Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

ChemMedChem, 2007
Z. Pan, H. Scheerens, Shyr-Jiann Li, B. Schultz, P. Sprengeler, Leland C. Burrill, Rohan V Mendonca, M. Sweeney, K. Scott, P. Grothaus, D. Jeffery, J. Spoerke, L. Honigberg, P. Young, S. Dalrymple, J. Palmer   +15 more
semanticscholar   +1 more source

Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.

Journal of Medicinal Chemistry, 2022
Shan-liang Sun, Shih-han Wu, Jihui Kang, Yi-Yuan Ma, Lu Chen, P. Cao, Liang Chang, Ning Ding, Xin Xue, Nianyu Li, Zhi‐Hao Shi   +10 more
semanticscholar   +1 more source

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors

Ca-A Cancer Journal for Clinicians, 2011
Kiran K Turaga
exaly